Drug Trial Radar · NCT06564311
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
93
Planned (sponsor's estimate)
Start
Aug 26, 2024
Primary completion
Aug 28, 2025
Study completion Feb 2026
Sponsor
- Lead sponsor
- Zenas BioPharma (USA), LLCIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Conditions
- Relapsing Multiple Sclerosis
Interventions
ObexelimabDrug
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRIIb, resulting in down regulation of B cell activity
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative number of new GdE T1 hyperintense lesionsTime frame: Week 8 and Week 12
Locations
47 sites in 12 countries. Site status is shown where the registry gives one.
North Central Neurology
Cullman, Alabama
Center for Neurology and Spine
Phoenix, Arizona
Perseverance Research Center
Scottsdale, Arizona
Regina Berkovich MD PhD, Inc
West Hollywood, California
Aqualine Clinical Research
Naples, Florida
University of South Florida
Tampa, Florida
University of Massachusetts Medical School
Worcester, Massachusetts
Infusion Associates Plymouth
Plymouth, Minnesota
MS Center for Innovations in Care
St Louis, Missouri
Holy Name Medical Center
Teaneck, New Jersey
Boster Center for MS
Columbus, Ohio
North Texas Institute of Neurology and Headache
Plano, Texas
Center for Neurological Disorders
Greenfield, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Neuro-logisch Wien
Vienna, Austria
Rehabilitation & MS Center, Noorderhart Hospital
Overpelt, Belgium
AZ Delta-Deltalaan 1
Roeselare, Belgium
Tiantan Hospital, Capital Medical University
Beijing, China
The First Affiliation Hospital of Soochow University
Suzhou, China
Tianjin Medical University General Hospital
Tianjin, China
People's Hospital of Xinjiang Uyaur Autonomous Region
Ürümqi, China
Tongji Hospital, Tongji Medical Center of HUST
Wuhan, China
Klinicki bolnicki centar Zagreb
Zagreb, Croatia
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Nemocnice Jihlava
Jihlava, Czechia
General University Hospital Praha
Prague, Czechia
Aalborg Universitetshospital
Aalborg, Denmark
Attikon University General Hospital
Chaïdári, Greece
University General Hospital of Larissa
Larissa, Greece
Fondazione Isituto G. Giglio di Cefalu
Cefalù, Italy
University of Florence
Florence, Italy
Istituto Neurologico Mediterraneo Neuromed
Pozzilli, Italy
Fondazione PTV Policlinico Tor Vergata
Roma, Italy
Neurocentrum Bydgoszcz sp.z o.o.
Bydgoszcz, Poland
M.A. LEK A.M. Maciejowsy Spolka Cywilna
Katowice, Poland
Zanamed Medical Clinic Sp z o.o.
Lublin, Poland
Wielospecjalistyczne Centrum Medyczne Ibismed
Zabrze, Poland
Hospital Clinico San Carlos
Madrid, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Hospital Regional Universitario de Malaga - Hospital General
Málaga, Spain
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.